Systemic sclerosis & Raynaud's
Polypharmacy, drug-drug interactions, and adverse drug reactions among systemic sclerosis patients: A cross-sectional risk factor study.
Authors' conclusion
SSc patients are significantly exposed to polypharmacy, DDIs and related ADRs, particularly in cases of severe illness, and especially if 5 or more medications are prescribed.
Study context
- Population
- SSc patients admitted to the daily scleroderma clinic between January 2020 and April 2022
- Participants
- 108 patients
- Exposure
- Drug-drug Interactions (DDIs) vs No DDIs vs Adverse Drug Reaction (ADRs) vs No ADRs
- DDIsn = 72
- ADRsn = 6
- Outcome
- Prevalence and determinants of DDI and ADR
- Follow-up
- One-year (ADR)
Methodological detailsretrospective analysis, multivariate analysis, DDI identified using 2 prescription analysis applications; adjudicated related ADRs reported
- Retrospective analysis
- Multivariate analysis
- DDI identified using 2 prescription analysis applications; adjudicated related ADRs reported
Main finding
As reported in the abstract
Prevalence of DDIs on prescriptions at inclusion
DDIs
66.7 %
72
Observational data: associations, not effects.
Further findings
Number of prescribed medications as determinant of DDIs (multivariate)
| OR (CI) | P value | ||
|---|---|---|---|
| Number of prescribed medications | 2.25 (1.52–3.32) | P < 0.0001 | |
| 0.20.5125Odds ratio (log scale) |
Number of prescribed medications as determinant of ADRs (multivariate)
| OR (CI) | P value | ||
|---|---|---|---|
| Number of prescribed medications | 1.68 (1.17–2.40) | P < 0.01 | |
| 0.512Odds ratio (log scale) |
| Outcome | DDIs | No DDIs | ADRs | No ADRs | P value |
|---|---|---|---|---|---|
| Number of medications, patients with vs without DDIsSpread printed in brackets, kind not named | 7 (range 5–10) | 3 (range 2–5) | — not stated in the abstract | — not stated in the abstract | P < 0.0001 |
| Number of medications, patients with vs without ADRsSpread printed in brackets, kind not named | — not stated in the abstract | — not stated in the abstract | 14 (range 10–18) | 7 (range 5–10) | P < 0.001 |
| Number of DDIs, patients with vs without ADRsSpread printed in brackets, kind not named | — not stated in the abstract | — not stated in the abstract | 12 (range 7–32) | 3 (range 1–6) | P < 0.001 |
— not stated in the abstract
Number of medications per patient
- Median number of medications per patient
- 6 [4-9]
- 5 or more medications
- 71 (65.7 %)
- 10 or more medications
- 23 (21.3 %)
Safety
- ADRs during one-year follow-up
- 8.3 · 6 of 6
Original publication
Polypharmacy, drug-drug interactions, and adverse drug reactions among systemic sclerosis patients: A cross-sectional risk factor study. Semin Arthritis Rheum. Published 20 May 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →